MnO2 nanodrug mediates the expression of antigen-presenting cell through combined chemotherapy to enhance the antineoplastic curative function

Abstract

Nano-conjugated compounds are studied in tumor treatment. However, little is known on the function of MnO2 nanodrug mediated by combined chemotherapy. This study explored the efficacy of MnO2 nanodrug applied in combined chemotherapy and evaluated its antineoplastic efficacy in vivo. Confocal microscope was used to detect the transfection efficiency in tumor cells. Nanoparticles with MnO2 as core (MnO2 NPs) were prepared. The antineoplastic activity efficiency of MnO2 NPs loaded with doxorubicin (DOX) was tested by cell viability test and cell biological behaviors. And the proliferation activity of the co-loading complex on tumor cells was tested in mice in vivo. RT-PCR and flow cytometry detected the expression of adenomatous polyposis coli (APC) mediated by MnO2 nanodrug combined chemotherapy. Co-loading MnO2 NPs and DOX showed a high activity on cells. The mobility of MnO2 NPs DOX cells was weakened and co-loading could inhibit cell invasion. The in vivo studies showed that the metastasis of tumor cells was inhibited after the mice received co-loading. Compared with DOX group, ki67 and APC in co-loading group decreased significantly and the expression of IFN-γ mediated by co-loading drugs was higher than control group, indicating that APC is involved in inhibiting tumor cell growth and metastasis by co-loading. MnO2 nanodrug can enhance the antineoplastic function through APC mediated by combined chemotherapy and inhibit the tumor growth by enhancing the synergistic function of inhibiting the growth, migration, and invasion of tumor cells.